Abstract:Background Salt‐sensitive hypertension is highly prevalent and associated with cardiorenal damage. Large clinical trials have demonstrated that SGLT2 (sodium‐glucose cotransporter 2) inhibitors exert hypotensive effect and cardiorenal protective benefits in patients with hypertension with and without diabetes. However, the underlying mechanism remains elusive. Methods and Results Dahl salt‐sensitive rats and salt‐insensitive controls were fed with 8% high‐salt diet and some of them were treated with canagliflozin. The blood pressure, urinary sodium excretion, and vascular function were detected. Transient receptor potential channel 3 (TRPC3) knockout mice were used to explain the mechanism. Canagliflozin treatment significantly reduced high‐salt‐induced hypertension and this effect was not totally dependent on urinary sodium excretion in salt‐sensitive hypertensive rats. Assay of vascular function and proteomics showed that canagliflozin significantly inhibited vascular cytoplasmic calcium increase and vasoconstriction in response to high‐salt diet. High salt intake increased vascular expression of TRPC3 in salt‐sensitive rats, which could be alleviated by canagliflozin treatment. Overexpression of TRPC3 mimicked salt‐induced vascular cytosolic calcium increase in vitro and knockout of TRPC3 erased the antihypertensive effect of canagliflozin. Mechanistically, high‐salt‐induced activation of NCX1 (sodium‐calcium exchanger 1) reverse mode increased cytoplasmic calcium level and vasoconstriction, which required TRPC3, and this process could be blocked by canagliflozin. Conclusions We define a previously unrecognized role of TRPC3/NCX1 mediated vascular calcium dysfunction in the development of high‐salt‐induced hypertension, which can be improved by canagliflozin treatment. This pathway is potentially a novel therapeutic target to antagonize salt‐sensitive hypertension. Nonstandard Abbreviations and Acronyms [Ca 2+ ]cyt cytosolic free calcium concentration NCX1 sodium‐calcium exchanger 1 ND normal diet SGLT2i sodium‐glucose exchanger 2 inhibitor SS Dahl salt‐sensitive rats SS‐19BN Dahl salt‐insensitive rats TRPC3 transient receptor potential channels 3 Clinical Perspective What Is New? The SGLT2 (sodium‐glucose cotransporter 2) inhibitor canagliflozin antagonizes salt‐induced hypertension in salt‐sensitive rats by directly alleviating vasoconstriction. Salt‐induced vascular transient receptor potential channel 3 upregulation results in an augmented vasoconstriction in salt‐sensitive hypertensive rats through facilitating NCX1 (sodium‐calcium exchanger 1)‐mediated vascular calcium uptake, which could be alleviated by canagliflozin. What Are the Clinical Implications? Antagonizing the interaction between transient receptor potential channel 3 and NCX1 by the SGLT2 inhibitor canagliflozin would represent a novel target to antagonize salt‐sensitive hypertension. Canagliflozin exerts its antihypertensive effect beyond its canonical effect on renal natriuresis. Cardiovascular disease has always been the biggest threat to human health. 1 Chronic vascular diseases such as hypertension and atherosclerosis are the main pathogenic factors or early pathological processes of high‐mortality diseases such as coronary heart disease, myocardial infarction, and heart failure. High salt intake not only acts as an independent risk factor for hypertension but also causes cardiovascular and renal damage. 2 , 3 High salt intake raises blood pressure (BP) through activation of the sympathetic nerve system and renin‐angiotensin system and leads to renal sodium retention. 4 Modest reduction in dietary salt intake substantially reduces cardiovascular events in the general population, but daily salt intake has remained unchanged in the past 2 decades. 5 , 6 Thus, to identify an alternative therapy for reducing t -Abstract Truncated-

S-18-3: SGLT2 INHIBITOR CANAGLIFLOZIN ANTAGONIZES SALT-SENSITIVE HYPERTENSION THROUGH MODIFYING TRPC3 MEDIATED VASCULAR CALCIUM HANDLING

Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt-Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling.

Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 expression

Canagliflozin attenuates kidney injury, gut-derived toxins, and gut microbiota imbalance in high-salt diet-fed Dahl salt-sensitive rats

Effect of SGLT2 and dual SGLT1/2 Inhibition on the Development of Salt-induced Hypertension

Calcitriol ameliorates renal injury with high-salt diet-induced hypertension by upregulating GLIS2 expression and AMPK/mTOR-regulated autophagy

EMPAGLIFLOZIN IMPROVES IMPAIRED SENSITIVITY OF AFFERENT NEURONS WITH RENAL AXONS

Abstract 074: Empagliflozin Improves Impaired Sensitivity Of Afferent Neurons With Renal Axons

Water and sodium conservation response induced by SGLT2 inhibitor ipragliflozin in Dahl salt-sensitive hypertensive rats

Dietary Cinnamaldehyde Activation of TRPA1 Antagonizes High-Salt-Induced Hypertension Through Restoring Renal Tubular Mitochondrial Dysfunction

Abstract P281: Urinary Metabolites Associated With Blood Pressure on a Low- or High-sodium Diet

OS 17-03 ENHANCED SGLT2 FUNCTION REDUCES NATRIURESIS IN DIABETIC MICE

Effect of SGLT2 Inhibition on the transcriptomic and proteomic profile of non-diabetic Dahl SS Rats

Urinary Metabolites Associated With Blood Pressure On A Low- Or High-Sodium Diet.

Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench

RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor

Dapagliflozin Attenuates Sodium Chloride Cotransporter (NCC) Protein Expression while Improving Urine Osmolality and Decreasing Blood Pressure in Hypertensive Diabetic db/db Mice

High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney Disease

VEGFC ameliorates salt-sensitive hypertension and hypertensive nephropathy by inhibiting NLRP3 inflammasome via activating VEGFR3-AMPK dependent autophagy pathway

Abstract 14007: Sodium-Dependent Glucose Transporters 2 Inhibition Ameliorates Obesity-Induced Metabolic Changes and Cardiomyopathy

Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and Inflammation